Novartis AG · NR3C1 · 小分子
triamcinolone acetonide 是一种小分子，由Novartis AG研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intraocular Injection。
| 商品名 | Triesence |
| 公司 | Novartis AG |
| 药物类别 | 小分子 |
| 分子靶点 | NR3C1 |
| 给药途径 | Injectable (Others), Intraocular Injection |
| 状态 | Approved |
triamcinolone acetonide 作用于 1 个分子靶点：
| NR3C1 | nuclear receptor subfamily 3 group C member 1 (GR, GCCR) |
triamcinolone acetonide 针对 3 个适应症，涉及 3 个治疗领域。
| 治疗领域 | 疾病/病症 | 分期 |
|---|---|---|
| Surgical and medical procedures | Adjuvant therapy | ✓ Approved |
| Eye disorders | Uveitis | ✓ Approved |
| Injury, poisoning and procedural complications | Vascular access site inflammation | ✓ Approved |
Rebollo Caballero Blanca B, Ruiz Martínez Javier J, Gómez-Olit Pérez Manuel M, Romera Pallarés Juan C JC
Mamizadeh Hamed H, Herizchi Ghadim Hamideh H, Pourasghary Sajjad S
To evaluate whether adding topical 5% caffeine to fluocinolone acetonide 0.025% cream (FAC) improves short-term clinical outcomes compared with FAC alone in patients with chronic plaque psoriasis. This randomized, parallel-group, masked, active-controlled clinical trial included 40 patients with chronic plaque psoriasis treated at the dermatology outpatient clinic of Sina Hospital, Tabriz, Iran. Participants were randomly allocated in a 1:1 ratio to receive either topical 5% caffeine plus fluocinolone acetonide 0.025% (intervention group, n=20) or topical fluocinolone acetonide 0.025% alone (control group, n=20). Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI) at baseline and weekly for four weeks. Treatment response and adverse events were also recorded. Baseline PASI scores were comparable between the intervention and control groups (3.41 ± 1.86 vs 3.79 ± 1.51, respectively; P=0.484). PASI scores were significantly lower in the intervention group at each post-treatment assessment. At week 4, mean PASI was 0.39 ± 0.17 in the intervention group and 2.29 ± 1.31 in the control group (P=0.001). The mean reduction from baseline to week 4 was 3.01 ± 1.48 with 5% caffeine plus FAC and 1.49 ± 1.01 with FAC alone (P<0.001). Complete clearance, defined as PASI=0, occurred in 14 of 20 patients (70%) in the intervention group compared with 1 of 20 (5%) in the control group (P=0.001). No adverse events were reported during the study. Adding topical 5% caffeine to FAC produced a greater short-term reduction in psoriasis severity than FAC alone. No adverse events were reported during the 4-week treatment period. Larger randomized trials with longer follow-up are warranted to confirm efficacy and characterize longer-term tolerability. Iranian Registry of Clinical Trials (IRCT), IRCT20091012002581N10, registered on October 28, 2023; https://irct.ir/trial/73367.
Qian Shengyan S, Cai Hengxing H, Khan Afsar A, Chen Bin B et al.
A new naturally occurring polyketide, pseurotin A3-10,11-acetonide (1), along with two known analogs, pseurotin A (2) and pseurotin A3 (3), was isolated from the culture broth of Streptomyces sp. CSDX076. The structures of these compounds were determined by extensive 1D and 2D nuclear magnetic resonance (NMR), ultraviolet (UV), and high-resolution electrospray ionization mass spectrometry (HRESIMS) spectroscopic analyses. All isolated compounds (1-3) were evaluated for antimicrobial activity against a panel of seven pathogenic strains using disc diffusion and broth microdilution methods. Notably, compound 1 exhibited moderate activity against Brucella melitensis with a minimum inhibitory concentration (MIC) of 8.0 μg/mL, while compound 2 showed weak activity against Staphylococcus epidermidis (MIC = 128.0 μg/mL); compound 3 was inactive against all tested strains. This study reports, for the first time, the antibacterial effects of these compounds against the respective pathogens.
AlShehri Amjad A, Alsakran Wael A WA, Badawi Abdulrahman H AH, Algethami Turki F TF et al.
To present the clinical features, management modalities, and response to treatment of the retinal vasoproliferative tumors (VPT) in a tertiary eye center. This is a retrospective interventional cohort study that included patients diagnosed with VPT between 2014 and 2024. The medical records of all patients were retrospectively reviewed. Eighteen eyes of 15 patients (44.12%) were included. The mean age of patients was 42.0 ± 12.6 years. The mean duration of follow-up was 70.6 ± 37.0 months. The most common location of VPT was inferotemporal (83.3%). Associated findings included subretinal fluid (100%), subretinal or intraretinal exudation (100%), and cystoid macular edema (66.7%). Significant visual improvements were achieved after intravitreal injections of bevacizumab, aflibercept, triamcinolone, and dexamethasone (P = 0.026), while significant reductions of the central subfoveal thickness were achieved after laser (P = 0.037) and pars plana vitrectomy (P = 0.034). Seven eyes had complete resolution, while 7 eyes had incomplete resolution, and 4 eyes had resistant tumors with clinical progression. The complete resolution type had significantly better visual outcomes than other types (P < 0.001). Subretinal fluid and intraretinal/subretinal exudations are prominent clinical features of VPT. There was a significant relationship between VPT classification based on the clinical response to treatment and the visual outcomes.
Hedhiri M H MH, Oueslati Y Y, Lajmi H H, Laajimi F F et al.
To systematically review the efficacy and safety of suprachoroidal injections of triamcinolone acetonide for the treatment of macular edema across various etiologies. A systematic literature search was conducted in PubMed/MEDLINE, Embase, Scopus, and Google Scholar for studies published between January 2010 and December 2025, in accordance with PRISMA 2020 guidelines. Randomized controlled trials, prospective and retrospective clinical studies, and meta-analyses evaluating suprachoroidal triamcinolone acetonide in adult patients with macular edema were included. Primary outcomes were changes in best-corrected visual acuity and central macular thickness. Secondary outcomes included intraocular pressure elevation, cataract progression, and serious ocular adverse events. Twelve primary clinical studies met the inclusion criteria, including phase 3 randomized controlled trials, one integrated phase 3 analysis, one phase 2 randomized trial, and multiple prospective and retrospective observational studies, comprising a total of 571 treated eyes/patients. High-quality evidence was available for non-infectious uveitic macular edema, where suprachoroidal triamcinolone acetonide resulted in significantly greater visual and anatomical improvement compared with sham treatment, with 47.4% of patients achieving a ≥ 15-letter gain in visual acuity at 24 weeks compared to 16.7% in the control group (RR=2.84; P<0.001). In diabetic macular edema, consistent anatomical improvement was observed, although functional outcomes were heterogeneous. Evidence in retinal vein occlusion was limited but suggested potential benefit, particularly when used in combination with anti-vascular endothelial growth factor therapy. Intraocular pressure elevation occurred in a minority of patients and was generally manageable. Cataract progression and serious ocular adverse events were uncommon. Suprachoroidal triamcinolone acetonide appears to be an effective and generally safe treatment option for macular edema, with the strongest evidence supporting its use in non-infectious uveitic macular edema. Evidence for diabetic macular edema and retinal vein occlusion remains limited, highlighting the need for further large-scale randomized controlled trials.
ElSheikh Reem H RH, Chauhan Muhammad Z MZ, Shakarachi Ahmed F AF, Sallam Ahmed B AB
To identify the common management pathways in the treatment of pseudophakic cystoid macular edema (CME). A retrospective cohort study was conducted from 2005 to 2024 using the TriNetX United States Collaborative Network. Patients diagnosed with pseudophakic CME were included in the study, and patients with retinal comorbidities were excluded. Treatments initiated after the diagnosis of pseudophakic CME, including topical corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs), periocular and intravitreal (IVT) corticosteroids, antivascular endothelial growth factor (anti-VEGF) injections, suprachoroidal corticosteroids, and pars plana vitrectomy (PPV), were tracked, and treatment sequences and imaging use over time were analyzed. A total of 23 035 patients met the inclusion criteria, with a mean age of 72 years; 54% were women, and 68% identified as White. The incidence of pseudophakic CME increased from 2.45% in 2005 to 17.6% in 2024. Optical coherence tomography (OCT) use increased over time, becoming the most common imaging modality (used in 90% of cases), while 20% of patients underwent no imaging. No treatment was documented in 40% of patients. Among those treated, 77% received topical corticosteroids and/ or NSAIDs as first-line therapy, followed by IVT steroids (7.4%), periocular steroids (6.5%), PPV (3.4%), and anti-VEGF injections (2%). IVT steroids were the most common second-line treatment (10.2%), primarily dexamethasone implants (82.8%), followed by triamcinolone (12.2%). Use of newer agents, including fluocinolone acetonide implants and suprachoroidal triamcinolone, was uncommon. Despite the increased use of OCT and earlier detection of subclinical cases, a substantial proportion of patients with pseudophakic CME have no documented treatment. Topical steroids and/ or NSAIDs represent the most common first- line therapy, with IVT steroids commonly used after inadequate response to treatment.
注册免费账户还可查看另外 9996 篇文献
免费注册查看全部文献 →